Bank of America Corp DE trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 16.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,906 shares of the biopharmaceutical company's stock after selling 20,550 shares during the period. Bank of America Corp DE owned 0.14% of Xenon Pharmaceuticals worth $4,191,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Quarry LP bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $78,000. Blue Trust Inc. increased its holdings in Xenon Pharmaceuticals by 140.3% in the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after acquiring an additional 1,414 shares during the last quarter. KBC Group NV increased its holdings in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 780 shares during the last quarter. Magnetar Financial LLC bought a new stake in Xenon Pharmaceuticals in the 4th quarter valued at $210,000. Finally, HighMark Wealth Management LLC increased its holdings in Xenon Pharmaceuticals by 22.0% in the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock valued at $239,000 after acquiring an additional 1,100 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Stock Up 2.2%
Shares of NASDAQ XENE traded up $0.65 during trading hours on Tuesday, hitting $30.72. 985,838 shares of the stock were exchanged, compared to its average volume of 547,035. The company has a market cap of $2.36 billion, a PE ratio of -10.89 and a beta of 1.21. The firm has a fifty day moving average price of $32.83 and a 200-day moving average price of $36.85. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same quarter last year, the firm earned ($0.62) EPS. As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price target on the stock. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price target for the company. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $54.82.
Get Our Latest Analysis on XENE
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
